Dapagliflozin
2 articles · search the full text for this term
-
SGLT2 Inhibitors in Heart Failure and Chronic Kidney Disease: Expanding Therapeutic Horizons beyond Glycemic Control
Abstract: Heart failure (HF) and chronic kidney disease (CKD) are closely related clinical diseases that significantly increase morbidity and death worldwide. The co-occurrence of both conditions is frequently referred to as the "cardio-renal syndrome," in which the failure of one organ hastens the decline of the other. The original purpose of sodium–glucose cotransporter-2 (SGLT2) inhibitors was to treat type 2 diabetic mellitus (T2DM) by reducing blood sugar levels. Nevertheless, new data …
Published in Research and Reviews: A Journal of Pharmacology · Vol. 16, Issue 2, 2026 Read article
-
Estimation of Alogliptin and Dapagliflozin in Synthetic Mixture by RP-HPLC Method
Abstract: The primary objective of the proposed research was to develop and validate analytical methods for the simultaneous quantification of Alogliptin and Dapagliflozin in a synthetic mixture. Alogliptin and Dapagliflozin are medications used for managing diabetes, with Alogliptin inhibiting the enzyme Dipeptidyl peptidase-4 and Dapagliflozin belonging to the class of sodium-glucose cotransporter 2 inhibitors. High-performance liquid chromatography method development was conducted using a C18 column (250 mmX4.6 mm, 5 μm particle …
Published in Research and Reviews: A Journal of Pharmaceutical Science · Vol. 15, Issue 2, 2024 · pp. 37–46 Read article